NERV - Minerva Neurosciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

71.27M

Cash

34.82M

Avg Qtr Burn

-5.191M

Short % of Float

0.37%

Insider Ownership

22.26%

Institutional Own.

30.32%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Roluperidone (5-HT2A antagonist) Details Mental health, Schizophrenia, Central nervous system illness	NDA Resubmission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Seltorexant (Orexin2 antagonist) Details Insomnia, Mood disorders	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.